

## ASX Announcement

9 August 2021

### *Lapse of Unlisted Share Options – correction*

Further to the Company's announcement regarding the lapse of 2,001,000 unlisted share options granted pursuant to Regeneus's option share trust plan, we note the correct total number of options remaining on issue following the lapse of these 2,001,000 options are as follows:

Number of Options	Exercise price	Expiry Date
1,250,000	\$0.20	31-Jan-24
3,800,000	\$0.1651	11-May-24
400,000	\$0.10	30-Sep-24
1,579,770	\$0.10	30-Jun-25
1,029,500	\$0.14	31-Aug-25
1,000,000	\$0.1075	31-Aug-25
5,000,000	\$0.10	24-May-26
5,000,000	\$0.10	24-May-26
15,000,000	\$0.10	24-May-26

-ENDS-

#### About Regeneus

Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza and Sygenus. Visit [www.regeneus.com.au](http://www.regeneus.com.au) for more information.

#### Authorisation & Additional information

This announcement was authorised by the Board of Directors of Regeneus Ltd

#### Investor and Media Contact

WE Communications  
T: 02 9237 2805  
E: [WE-AURegeneus@we-worldwide.com](mailto:WE-AURegeneus@we-worldwide.com)

For personal use only